Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Catholics and others around the world have been praying for the pope, a liberal reformer who has led the Church for almost 12 years.

The Vatican said the pope responded well to the treatment, with a good level of gas exchange, and remained conscious and alert at all times.

Furs have been on every catwalk this season, and Etro sent out some of the best yet. The show opened with a shaggy, majestic ...

"I fell into the trap," said a mother in the Boston area. She gained a few more hours of work, but lost her public assistance ...

Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

Tiziana Life Sciences (TLSA) announced that a nasal anti-CD3 preclinical study is nearing completion, and that foralumab could offer a novel ...

Long COVID is a complex and often debilitating complication following COVID-19 infection. It affects millions worldwide, presenting with symptoms such as persistent fatigue, cognitive impairment ...